Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meditor Pharmaceuticals has reported encouraging results from a Phase II, randomized double blind, placebo-controlled dose-escalating study in migraine patients.
Subscribe to our email newsletter
This Phase II study was designed to assess the pharmacokinetics, safety and efficacy of MTR-106 tablets in female patients suffering from migraine without aura. The study population consisted of 40 female patients. The average age of participants was 37 +/- 9 years.
The average duration of migraine attacks was 16.6 +/- 10 hours with a frequency of 2.8 +/- 1.3 attacks per month. The subjects were randomized in a ratio of 4:1 treatment to placebo respectively, constituting four groups of 10 patients each. Treatment arms of MTR-106 or placebo were administered at escalating doses of 25, 50, 75 and 100mg.
Analysis of the data showed that at two hours post-treatment significantly more subjects treated with MTR-106 had pain relief compared to those receiving placebo (71% and 25% respectively; p=0.025), and more patients treated with MTR-106 were pain free compared to those receiving placebo (26% and 13% respectively). Of those treated with MTR-106, 23% had sustained pain free at 24 hours post-treatment.
Adrian Harel, CEO of Meditor, said: “We are meeting with the regulatory authorities to further develop and commercialize the drug.”